Current Report Filing (8-k)
24 November 2016 - 8:32AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of Earliest Event Reported): November 17, 2016
Cytokinetics, Incorporated
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
000-50633
|
|
94-3291317
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(I.R.S. Employer
Identification No.)
|
|
|
|
280 East Grand Avenue, South San Francisco, California
|
|
|
|
94080
|
(Address of principal executive offices)
|
|
|
|
(Zip Code)
|
Registrants telephone
number, including area code: (650) 624 - 3000
Not Applicable
Former name or former address, if changed since last report
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item 5.02
|
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
|
On November 17, 2016, Sharon A. Barbari, Executive Vice President of Finance and Chief Financial Officer of Cytokinetics, Incorporated,
provided notice that she intends to retire in the second quarter of 2017. Ms. Barbari anticipates participating in the identification of her successor and assisting in a smooth transition of her responsibilities.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
CYTOKINETICS, INCORPORATED
|
|
|
|
|
Dated: November 23, 2016
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
|
/s/ Sharon A. Barbari
|
|
|
|
|
|
|
Sharon A. Barbari
Executive Vice President and
Chief Financial Officer
|
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2024 to May 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From May 2023 to May 2024